{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:18:01Z","timestamp":1791325081155,"version":"4.3.1"},"reference-count":58,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia Open"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the real\u2010world experience, comorbidities, and mental health of patients with epilepsy (PwE) who are currently receiving antiseizure medication (ASM) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A web\u2010enabled survey of PwE was conducted from July\u2013September 2023. Patients were recruited via patient panels or physician referrals. US residents, \u226518\u2009years old, with physician\u2010confirmed diagnosis of epilepsy for \u22651\u2009year, self\u2010reported focal seizures, \u22651 seizure per month, past\/present use of \u22652 ASMs, and currently receiving an ASM for \u22651\u2009month, were eligible. Self\u2010reported aspects of the treatment journey and disease burden were examined, including four validated patient\u2010reported outcome measures: Quality of Life in Epilepsy Inventory\u201010 (QOLIE\u201010), Patient Health Questionnaire\u20109 (PHQ\u20109), Generalized Anxiety Disorder\u20107 (GAD\u20107), and Work Productivity and Activity Impairment questionnaire (WPAI). Healthcare resource utilization and perceived levels of caregiver burden were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 170 patients surveyed, 66.5% reported &gt;1 seizure per month, 75.3% rated their seizures as moderate\u2010to\u2010highly severe, and 72.9% reported \u22653 non\u2010seizure symptoms despite ASM treatment. The most common non\u2010seizure symptoms were mood issues (76.5%), fatigue\/lack of energy (72.4%), and problems with sleep (68.8%). Anxiety (49.4%), migraines (40.6%), and depression (40.0%) were the top reported physician\u2010diagnosed comorbidities. The mean QOLIE\u201010 score was 44.5 (SD, 17.5), indicative of a notable impact on QoL. Overall, 63.5% and 46.5% of patients exhibited moderate\u2010to\u2010severe depression and anxiety based on PHQ\u20109 and GAD\u20107, respectively. Using the WPAI, 60.6% mean work productivity loss was observed, driven by presenteeism. Patients averaged 9.4 outpatient visits and 2.8 emergency visits and\/or hospitalizations annually. Of patients requiring caregivers (60.6%, n\u2009=\u2009103), 68.9% agreed day\u2010to\u2010day and emotional demands from their epilepsy negatively impacted their family\/caregivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance<\/jats:title>\n                    <jats:p>Collectively, these findings provide a broad perspective of the burden of illness experienced by PwE who are currently receiving treatment and demonstrate unmet needs for additional therapies that can improve patient experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary<\/jats:title>\n                    <jats:p>The primary treatment goals for epilepsy are to maximize seizure control, reduce side effects of medication, and improve quality of life. In our study, US patients with epilepsy currently using antiseizure medications used a survey to report their perspectives on the epilepsy treatment journey and ongoing burdens from the disease. We found that despite receiving treatment, patients still had a high frequency\/severity of seizures, were dissatisfied with medication side effects, reported depression, anxiety, and reduced work productivity, and perceived that their disease had negative impacts on caregivers. New medications that improve the experience for patients with epilepsy are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epi4.70222","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:16:31Z","timestamp":1772990191000},"page":"452-465","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["What does it mean to live with epilepsy? Burden of illness from the patient perspective"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0790-8140","authenticated-orcid":false,"given":"Joanne M.","family":"Wagner","sequence":"first","affiliation":[{"name":"Xenon Pharmaceuticals Inc.  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5958-3656","authenticated-orcid":false,"given":"Bhagyashree","family":"Oak","sequence":"additional","affiliation":[{"name":"Trinity Life Sciences, LLC  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7071-4653","authenticated-orcid":false,"given":"Brittany","family":"Smith","sequence":"additional","affiliation":[{"name":"Trinity Life Sciences, LLC  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-5069","authenticated-orcid":false,"given":"Amod","family":"Athavale","sequence":"additional","affiliation":[{"name":"Trinity Life Sciences, LLC  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0069-6033","authenticated-orcid":false,"given":"Jeffrey R.","family":"Skaar","sequence":"additional","affiliation":[{"name":"Trinity Life Sciences, LLC  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9698-4159","authenticated-orcid":false,"given":"Alvin","family":"Ong","sequence":"additional","affiliation":[{"name":"Xenon Pharmaceuticals Inc.  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Harden","sequence":"additional","affiliation":[{"name":"Xenon Pharmaceuticals Inc.  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(24)00302-5"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6631a1"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12050"},{"key":"e_1_2_13_5_1","unstructured":"National Institute of Neurological Disorders and Stroke.Epilepsy and seizures. Accessed April 17 2024. Available from:https:\/\/www.ninds.nih.gov\/health\u2010information\/disorders\/epilepsy\u2010and\u2010seizures"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01579.x"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.33588\/rn.5707.2013214"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2016.0836"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3949"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00827-8"},{"key":"e_1_2_13_12_1","volume-title":"StatPearls","author":"Subbarao BS","year":"2024"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13769"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.05.011"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17140"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00437-0"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208087"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006425"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18089"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2024.100654"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00612.x"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.06.030"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.04.005"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/808421"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109297"},{"issue":"6","key":"e_1_2_13_26_1","first-page":"1","article-title":"Epilepsy surveillance among adults\u2010\u201019 states, behavioral risk factor surveillance system, 2005","volume":"57","author":"Kobau R","year":"2008","journal-title":"MMWR Surveill Summ"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01164"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1012486"},{"key":"e_1_2_13_29_1","unstructured":"American Academy of Neurology.Quality of Life in Epilepsy: QOLIE\u201010 and QOLIE\u201010\u2010P Scoring Instructions. Accessed April 2024. Available from:https:\/\/www.aan.com\/siteassets\/home\u2010page\/policy\u2010and\u2010guidelines\/quality\/quality\u2010measures\/epilepsy\u2010and\u2010seizures\/qolie10p\u2010scoring.pdf"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"e_1_2_13_33_1","unstructured":"Association WM.Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects (Helsinki: 1964; Amended Tokyo: 1975; Venice: 1983; Hong Kong: 1989; Republic of South Africa: 1996; Edinburgh: 2000; Washington: 2002; Tokyo 2004; Seoul 2008).2008."},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903126833"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.11.006"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.05.038"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.02.014"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2014.10.3.175"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.12.005"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.619854"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.8088"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201542"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/15357597231169553"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000874"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.10.030"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22940"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.30773\/pi.2019.02.01"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719001314"},{"key":"e_1_2_13_49_1","volume-title":"Symptoms of Depression Among Adults: United States, 2019","year":"2020"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.03.037"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106649"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13911"},{"key":"e_1_2_13_53_1","volume-title":"Symptoms of Generalized Anxiety Disorder Among Adults: United States, 2019","year":"2020"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000103282.62353.85"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2172282"},{"key":"e_1_2_13_56_1","doi-asserted-by":"crossref","unstructured":"SantoL KangK.National Ambulatory Medical Care Survey: 2019 National Summary Tables.https:\/\/doi.org\/10.15620\/cdc:123251","DOI":"10.15620\/cdc:123251"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.03.015"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-023-00265-5"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7597.2005.05106.x"}],"container-title":["Epilepsia Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.70222","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/epi4.70222","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.70222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:30:13Z","timestamp":1778934613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi4.70222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/epi4.70222"],"URL":"https:\/\/doi.org\/10.1002\/epi4.70222","archive":["Portico"],"relation":{},"ISSN":["2470-9239","2470-9239"],"issn-type":[{"value":"2470-9239","type":"print"},{"value":"2470-9239","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"2025-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}